The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process
Open accessAbstract
BACKGROUND: There is no consensus on core outcome domains for hidradenitis suppurativa (HS). Heterogeneous outcome measure instruments in clinical trials likely leads to outcome-reporting bias and limits the ability to synthesize evidence. OBJECTIVES: To achieve global multistakeholder consensus on a core outcome set (COS) of domains regarding what to measure in clinical trials for HS. METHODS: Six stakeholder groups participated in a Delphi process that included five anonymous e-Delphi rounds and four face-to-face consensus meetings to reach consensus on the final COS. The aim was for a 1 : 1 ratio of patients to healthcare professionals (HCPs). RESULTS: A total of 41 patients and 52 HCPs from 19 countries in four continents participated in the consensus process, which yielded a final COS that included five domains: pain, physical signs, HS-specific quality of life, global assessment and progression of course. A sixth domain, symptoms, was highly supported by patients and not by HCPs but is recommended for the core domain set. CONCLUSIONS: Routine adoption of the COS in future HS trials should ensure that core outcomes of importance to both patients and HCPs are collected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 2. Framing the question and deciding on important outcomes
Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., Alderson, P., Glasziou, P., Falck-Ytter, Y., & Schünemann, H. J. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.012 · Cited by 1,911
Developing core outcome sets for clinical trials: issues to consider
Williamson, P. R., Altman, D. G., Blazeby, J. M., Clarke, M., Devane, D., Gargon, E., & Tugwell, P. (2012) · Trials · doi:10.1186/1745-6215-13-132 · Cited by 1,661
Sinha, I. P., Smyth, R. L., & Williamson, P. R. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000393 · Cited by 891
Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0
Boers, M., Kirwan, J. R., Wells, G., Beaton, D., Gossec, L., d'Agostino, M.-A., Conaghan, P. G., Bingham, C. O., Brooks, P., Landewé, R., et al. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.11.013 · Cited by 781 · cited 2×
“17,19,23,24 Six groups of stakeholders were invited to participate in our development process: patients, dermatology HS experts, surgical HS experts, HS nurses, industry representatives and drug regulatory authorities.”
Core outcome set–STAndards for reporting: the COS-STAR statement
Kirkham, J. J., Gorst, S., Altman, D. G., Blazeby, J. M., Clarke, M., Devane, D., Gargon, E., Moher, D., Schmitt, J., Tugwell, P., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002148 · Cited by 650
Schmitt, J., Apfelbacher, C., Spuls, P. I., Thomas, K. S., Simpson, E. L., Furue, M., Chalmers, J., & Williams, H. C. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.320 · Cited by 230
Cited by
Nguyen, T. V., Damiani, G., Orenstein, L. A. V., Hamzavi, I., & Jemec, G. B. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16677 · Cited by 391
Self-citationDe Meyer, D., Kottner, J., Beele, H., Schmitt, J., Lange, T., Van Hecke, A., Verhaeghe, S., & Beeckman, D. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.03.011 · Cited by 119
Metadata
- Authors
- Thorlacius, L., Ingram, J. R., Villumsen, B., Esmann, S., Kirby, J. S., Gottlieb, A. B., Merola, J. F., Dellavalle, R., Nielsen, S. M., Christensen, R., Garg, A., Jemec, G. B. E., & on behalf of the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC)
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-07-05
- Volume
- 179
- Issue
- 3
- Pages
- 642-650
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W2797970907
- Cited by
- 180
- References
- 6
- FWCI
- 15.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.